1. Scrip
  2. >>Business

Dermira Ends UCB Cimzia Psoriasis Pact To Focus On Its Own Pipeline

 
• By Sten Stovall

As it ends its pact with UCB, Dermira says it needs to focus on its own top assets and couldn't simultaneously launch Cimzia in psoriasis.

Skin condition
Demira Ends UCB Cimza Psoriasis Pact To Focus On Own Dermatology • Source: Shutterstock

Dermira Inc. is ending its partnership with UCB SA developing the Belgian company's biologic Cimzia (certolizumab pegol) in the US, EU and Canada for the treatment of psoriasis to fully focus on its own dermatological assets, two of which are in pivotal Phase III trials.

‍Dermira in-licensed Cimzia, a marketed rheumatoid arthritis drug, from UCB in 2014 which Dermira has been developing for plaque psoriasis, an increasingly crowded market

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.